Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic ...
Dec 11, 2019 · The inclusion of patients with brain metastases in the initial phase 1 trials of tucatinib generated preliminary efficacy data to support their inclusion in HER2CLIMB and is in line with …
HER2CLIMB-05: Tucatinib Plus HP in HER2+ MBC - oncodaily.com
Dec 12, 2025 · Conclusions HER2CLIMB-05 demonstrated that the addition of tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab resulted in a statistically significant and …
TUKYSA Combination Significantly Improves Progression-Free ... - Pfizer
Oct 14, 2025 · HER2CLIMB-05 is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA ® (tucatinib) compared to placebo, both in combination …
Dec 14, 2025 · “The HER2CLIMB-05 trial was initiated to investigate the efficacy of tucatinib in a first-line maintenance setting in patients with HER2-positive metastatic breast cancer who completed …
Adding Tukysa Delays Growth of Metastatic HER2+ Breast Cancer
3 days ago · Results from the HER2CLIMB-05 trial show that adding Tukysa (chemical name: tucatinib) to maintenance therapy controls cancer growth better than Herceptin and Perjeta alone. The …
HER2CLIMB was a global, randomized, double-blind controlled trial of adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases, who were previously treated with …
Advancing treatment in HER2-positive metastatic breast cancer
Jul 7, 2025 · Abstract Tucatinib has significantly advanced the treatment of HER2-positive metastatic breast cancer. When used in combination with trastuzumab and capecitabine, it improves survival for …
SABCS 2025 – Pfizer could battle itself in first-line maintenance
Dec 10, 2025 · Pfizer’s small-molecule HER2 inhibitor Tukysa looks set to move into early HER2-positive breast cancer after showing a convincing benefit in first-line maintenance. The Her2climb-05 …
Experts Highlight SABCS 2025 Data With Potential to Shift Breast …
5 days ago · Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.
Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 …
May 2, 2024 · This is the first report of HER2CLIMB-02 (NCT03975647), a randomized, double-blind, placebo-controlled phase 3 study assessing the efficacy and safety of tucatinib combined with T …